Stifel Financial Corp boosted its holdings in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 37.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 197,697 shares of the company's stock after purchasing an additional 53,673 shares during the quarter. Stifel Financial Corp owned about 0.31% of Evolus worth $2,183,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. KBC Group NV acquired a new position in shares of Evolus during the fourth quarter valued at about $49,000. IFP Advisors Inc raised its holdings in Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after acquiring an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Evolus in the 4th quarter valued at approximately $106,000. Quantbot Technologies LP bought a new stake in shares of Evolus in the 4th quarter worth approximately $118,000. Finally, Tradition Wealth Management LLC grew its holdings in shares of Evolus by 18.2% during the 4th quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock worth $144,000 after purchasing an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.
Insider Buying and Selling at Evolus
In other news, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $12.40, for a total value of $77,512.40. Following the completion of the transaction, the insider now owns 508,619 shares in the company, valued at approximately $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rui Avelar sold 27,904 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $370,007.04. Following the sale, the insider now owns 362,467 shares in the company, valued at approximately $4,806,312.42. This trade represents a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 60,575 shares of company stock worth $794,369 over the last ninety days. Corporate insiders own 5.90% of the company's stock.
Wall Street Analyst Weigh In
EOLS has been the subject of several research reports. Barclays raised their target price on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. BTIG Research started coverage on shares of Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective for the company. Needham & Company LLC reissued a "buy" rating and issued a $22.00 target price on shares of Evolus in a research note on Thursday. Finally, HC Wainwright restated a "buy" rating and set a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Evolus presently has a consensus rating of "Buy" and a consensus price target of $23.75.
View Our Latest Report on EOLS
Evolus Price Performance
Shares of NASDAQ:EOLS traded down $0.29 on Friday, hitting $9.80. The stock had a trading volume of 1,361,358 shares, compared to its average volume of 672,080. The firm's 50 day moving average price is $11.66 and its 200-day moving average price is $12.56. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus, Inc. has a twelve month low of $8.67 and a twelve month high of $17.82. The company has a market capitalization of $631.82 million, a price-to-earnings ratio of -10.77 and a beta of 1.11.
About Evolus
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
See Also
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
